Antibody-drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management
| Autor: | Soumya Sucharita Pattnaik, Kh. Reeta, Pranav Sopory, Sudhir Chandra Sarangi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
Oncology medicine.medical_specialty Immunoconjugates medicine.medical_treatment media_common.quotation_subject Antineoplastic Agents Review Article 030226 pharmacology & pharmacy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Cancer immunotherapy Drug Development Internal medicine Neoplasms metronomic chemotherapy Medicine Animals Humans Pharmacology (medical) Antibody–drug conjugates 030212 general & internal medicine media_common Pharmacology trastuzumab emtansine cancer immunotherapy biology business.industry Drug discovery Cancer medicine.disease Metronomic Chemotherapy Progression-Free Survival Clinical trial Survival Rate tisagenlecleucel chemistry Trastuzumab emtansine Administration Metronomic biology.protein Quality of Life Immunotherapy Antibody business |
| Zdroj: | Indian Journal of Pharmacology |
| ISSN: | 1998-3751 |
| Popis: | Treatment of cancer is a major challenge even though the pathophysiology is becoming clearer with time. A number of new chemical entities are developed to target cancer growth inhibition, but the targeted delivery of these products still needs novel research. This is of utmost importance not only for higher efficacy but also for a reduction in systemic toxicity and cost of treatment. Although multiple novel targets and molecules are being researched, most of them could not pass the regulatory approval process, due to low benefit-risk ratio and lack of target specificity. Failure of a majority of these drugs was in part due to their superiority claimed via surrogate markers. Despite these, currently, more than 100 chemotherapeutic agents are in practice. This review paper discusses in detail the molecular basis, drug discovery, and pros and cons over conventional treatment approaches of three novel approaches in cancer therapy, i.e., (i) antibody-drug conjugates, (ii) cancer immunotherapy, and (iii) metronomic chemotherapy. All the drugs developed using these three novel approaches were compared against the established treatment regimens in clinical trials with clinical end points, such as overall survival, progression-free survival, and quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|